Last reviewed · How we verify

NCT03525990

Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients

Completed NA Last updated 21 April 2023
What this trial tests

NA trial testing Questionnaires in Breast Neoplasm Malignant Female in 62 participants. Completed in 30 April 2022.

Timeline
10 January 2018
Primary endpoint
30 April 2022
30 April 2022

Quick facts

Lead sponsorDr. Vera Trommet
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposehealth services research
Enrollment62
Start date10 January 2018
Primary completion30 April 2022
Estimated completion30 April 2022
Sites2 locations across Austria

Drugs / interventions tested

Conditions studied

Sponsor

Dr. Vera Trommet

Who can join

Eligibility, female only, with Breast Neoplasm Malignant Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PRO-COM Project: Randomized-controlled study evaluating the impact of electronic patient reported outcome (ePRO) surveys on patient-physician communication and quality of life in patients with advanced breast cancer

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Questionnaires

Trials testing the same drug.

Other recruiting trials for Breast Neoplasm Malignant Female

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03525990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing